Korean Journal of Pediatrics10.3345/kjp.2019.000172019628312-316Evaluation of hematologic profile may be needed for patients treated with oxcarbazepineGu Hyun Jung, Su Jeong You,,
Journal of the American Geriatrics Society10.1111/j.1532-5415.2005.53528_3_1.x200553101834-1836IS ESTABLISHING AN APPROPRIATE BLEEDING RISK PROFILE IN ELDERLY PATIENTS TREATED WITH LOW-MOLECULAR-WEIGHT HEPARINS NEEDED?Enrique Anton, Juan Marti,
Seizure10.1016/j.seizure.2015.07.018201531149-154Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapyAnnika Sattler, Marion Schaefer, Theodor W. May,
Epilepsy Research10.1016/0920-1211(94)90091-4199419179-85Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal®) on a named-patient basisJohan A.P. Van Parys, Harry Meinardi,
Epilepsia10.1111/j.1528-1167.2009.02489.x2010515818-829Safety profile of oxcarbazepine: Results from a prescription-event monitoring studyYvonne Buggy, Deborah Layton, Carole Fogg, Saad A.W. Shakir,
Korean Journal of Pediatrics10.3345/kjp.2019.004722019628299-300Why should we monitor for hematologic adverse drug reactions to oxcarbazepine?Gwang Cheon Jang,,
Cerebrovascular Diseases Extra10.1159/000363050201442115-121Evaluation of the Implementation of a Rapid Response Treatment Protocol for Patients with Acute Onset Stroke: Can We Increase the Number of Patients Treated and Shorten the Time NeededRajiv Advani, Halvor Naess, Martin W. Kurz,
Medical Management of the Surgical Patient10.1016/b978-141602385-2.50007-x2008117-156Perioperative Evaluation of Patients with Hematologic DisordersFREDERICK M. FELLIN,
Principles and Practice of Cancer Infectious Diseases10.1007/978-1-60761-644-3_5201147-66Infections in Patients with Hematologic Malignancies Treated with Monoclonal Antineoplastic TherapyAndré Goy, Susan O’Brien
European Urology Supplements10.1016/s1569-9056(14)60721-12014131e732-e732b732 Pathological T2b and T2c subgrouping may not be needed for predicting biochemical relapse in patients treated by radical prostatectomyK. Mitsuzuka, S. Narita, T. Koie, S. Kawamura, T. Tochigi, T. Habuchi, C. Ohyama, Y. Arai,